

## Anställning

### Professor, Docent,Handledare

Infektionsmedicin  
Lunds universitet  
Lund, Sverige  
2015 sep. 21 → present

### Projektledare

Infektion och immunmodulering  
Lunds universitet  
Lund, Sverige  
2016 juni 23 → present

### Prefekt

Institutionen för kliniska vetenskaper, Lund  
Lunds universitet  
Lund, Sverige  
2025 jan. 1 → present

## Forskningsoutput

### Immunomodulating Enzymes from *Streptococcus pyogenes*-In Pathogenesis, as Biotechnological Tools, and as Biological Drugs

Happonen, L. & Collin, M., 2024 jan. 18, I: *Microorganisms*. 12, 1, 200.

### Hydroxyapatite: An Antibiotic Recruiting Moiety for Local Treatment and Prevention of Bone Infections

Sebastian, S., Huang, J., Liu, Y., Tandberg, F., Collin, M., Puthia, M. & Raina, D. B., 2024, I: *Journal of Orthopaedic Research*. 42, 1, s. 212-222

### Pathogen-driven degradation of endogenous and therapeutic antibodies during streptococcal infections

Toledo, A. G., Bratanis, E., Velásquez, E., Chowdhury, S., Olofsson, B., Sorrentino, J. T., Karlsson, C., Lewis, N. E., Esko, J. D., Collin, M., Shannon, O. & Malmström, J., 2023 okt. 23, I: *Nature Communications*. 14, s. 1-16 6693.

### Bacterial Pathogenesis: Methods and Protocols

Collin, M. (redaktör) & Nordenfelt, P. (redaktör), 2023 maj 31, 2 uppl. Humana Press. 337 s. (Methods in Molecular Biology; vol. 2674)

### A calcium sulphate/hydroxyapatite ceramic biomaterial carrier for local delivery of tobramycin in bone infections: Analysis of rheology, drug release and antimicrobial efficacy

Huang, J., Sebastian, S., Collin, M., Tägil, M., Lidgren, L. & Raina, D. B., 2023, I: *Ceramics International*. 49, 21, s. 33725-33734

### Expression of the Bacterial Enzyme IdeS Using a GFP Fusion in the Yeast *Saccharomyces cerevisiae*

Lindh, T., Collin, M., Lood, R. & Carlquist, M., 2023, *Bacterial pathogenesis: Methods and protocols*. Nordenfelt, P. & Collin, M. (red.). 2nd uppl. Humana Press, s. 131-146 (Methods in molecular biology (Clifton, N.J.)).

### Preface

Nordenfelt, P. & Collin, M., 2023, *Bacterial Pathogenesis - Methods and Protocols*. Nordenfelt, P. & Collin, M. (red.). 2nd uppl. Humana Press, Vol. 2674. s. v-vi (Methods in Molecular Biology).

### Systemic rifampicin shows accretion to locally implanted hydroxyapatite particles in a rat abdominal muscle pouch model

Sebastian, S., Huang, J., Liu, Y., Collin, M., Tägil, M., Raina, D. B. & Lidgren, L., 2023, I: *Journal of Bone and Joint Infection*. 8, 1, s. 19-28

### **Bakterienzymer lurar immunförsvaret**

Collin, M., 2022 nov. 12, Vetenskap & Hälsa.

### **Extended local release and improved bacterial eradication by adding rifampicin to a biphasic ceramic carrier containing gentamicin or vancomycin**

Sebastian, S., Tandberg, F., Liu, Y., Raina, D. B., Tägil, M., Collin, M. & Lidgren, L., 2022 nov., I: Bone & joint research. 11, 11, s. 787-802 16 s.

### **Multiple modes of action mediate the therapeutic effect of IVIg in experimental epidermolysis bullosa acquisita**

Pipi, E., Kasprick, A., Iwata, H., Goletz, S., Hundt, J. E., Sadeghi, H., Schmidt-Jiménez, L. F., Schmidt, E., Sjögren, J., Zillikens, D., Ludwig, R. J., Collin, M. & Bieber, K., 2022, I: Journal of Investigative Dermatology. 142, 6, s. 1552-1564.e8

### **Archaea in Blood Cultures: Coincidence or Coinfection?**

Rasmussen, M. & Collin, M., 2021 nov. 1, I: Clinical Infectious Diseases. 73, 9, s. E2580-E2581

### **IgG Fc sialylation is regulated during the germinal center reaction upon immunization with different adjuvants**

Bartsch, Y. C., Eschweiler, S., Leliavski, A., Lunding, H. B., Wagt, S., Petry, J., Lilienthal, G.-M., Rahmöller, J., de Haan, N., Hölscher, A., Erapanedi, R., Giannou, A. D., Aly, L., Sato, R., de Neef, L. A., Winkler, A., Braumann, D., Hobusch, J., Kuhnigk, K. & Krémer, V. och 19 andra, Steinhaus, M., Blanchard, V., Gemoll, T., Habermann, J. K., Collin, M., Salinas, G., Manz, R. A., Fukuyama, H., Korn, T., Waisman, A., Yogev, N., Huber, S., Rabe, B., Rose-John, S., Busch, H., Berberich-Siebelt, F., Hölscher, C., Wuhrer, M. & Ehlers, M., 2020 sep. 1, I: The Journal of Allergy and Clinical Immunology. 146, 3, s. 652-666 15 s.

### **Antibody glycosylation as an immunological key in health and disease**

Collin, M., 2020 mars 20, I: Glycobiology. 30, 4, s. 200-201

### **Streptococcus pyogenes evades adaptive immunity through specific IgG glycan hydrolysis**

Nägeli, A., Bratanis, E., Karlsson, C., Shannon, O., Kalluru, R., Linder, A., Malmström, J. & Collin, M., 2019 juli 1, I: Journal of Experimental Medicine. 216, 7, s. 1615-1629

### **Cartilage-binding antibodies induce pain through immune complex-mediated activation of neurons**

Bersellini Farinotti, A., Wigerblad, G., Nascimento, D., Bas, D. B., Morado Urbina, C., Nandakumar, K. S., Sandor, K., Xu, B., Abdelmoaty, S., Hunt, M. A., Ångeby Möller, K., Baharpoor, A., Sinclair, J., Jardemark, K., Lanner, J. T., Khmaladze, I., Borm, L. E., Zhang, L., Wermeling, F. & Cragg, M. S. och 11 andra, Lengqvist, J., Chabot-Doré, A.-J., Diatchenko, L., Belfer, I., Collin, M., Kultima, K., Heyman, B., Jimenez-Andrade, J. M., Codeluppi, S., Holmdahl, R. & Svensson, C. I., 2019, I: Journal of Experimental Medicine. 216, 8, s. 1904-1924

### **Comments on letter to the editor by Faniyan et al. in response to Imported leishmaniasis in Sweden 1993-2016**

Söbirk, S. K., Inghammar, M., Collin, M. & Davidsson, L., 2019, I: Epidemiology and Infection. 47, s. e47

### **Chronic active arthritis driven by macrophages without involvement of T cells: A Novel Experimental Model of Rheumatoid Arthritis**

Hagert, C., Sareila, O., Kelkka, T., Nandakumar, K. S., Collin, M., Xu, B., Guérard, S., Bäcklund, J., Jalkanen, S. & Holmdahl, R., 2018 aug., I: Arthritis & Rheumatology. 70, 8

### **Streptococcal Endo-β-N-Acetylglucosaminidase Suppresses Antibody-Mediated Inflammation In Vivo**

Nandakumar, K. S., Collin, M., Happonen, K. E., Lundström, S. L., Croxford, A. M., Xu, B., Zubarev, R. A., Rowley, M. J., Blom, A. M., Kjellman, C. & Holmdahl, R., 2018 juli 16, I: Frontiers in Immunology. 9, 1623.

### **Imported leishmaniasis in Sweden 1993-2016**

Karlsson Söbirk, S., Inghammar, M., Collin, M. & Davidsson, L., 2018, I: Epidemiology and Infection. 146, 10, s. 1267-1274

### **Sialylation of IgG antibodies inhibits IgG-mediated allergic reactions**

Epp, A., Hobusch, J., Bartsch, Y. C., Petry, J., Lilienthal, G.-M., Koeleman, C. A. M., Eschweiler, S., Möbs, C., Hall, A., Morris, S. C., Braumann, D., Engellenner, C., Bitterling, J., Rahmöller, J., Leliavski, A., Thurmann, R., Collin, M., Moremen, K. W., Strait, R. T. & Blanchard, V. och 12 andra, Petersen, A., Gemoll, T., Habermann, J. K., Petersen, F., Nandy, A., Kahlert, H., Hertl, M., Wuhrer, M., Pfützner, W., Jappe, U., Finkelman, F. D. & Ehlers, M., 2018, I: *Journal of Allergy and Clinical Immunology*. 141, 1, s. 399-402.e8

### **In vivo enzymatic modulation of IgG antibodies prevents immune complex-dependent skin injury**

Mihai, S., Albert, H., Ludwig, R. J., Iwata, H., Björck, L., Collin, M. & Nimmerjahn, F., 2017 aug., I: *Experimental Dermatology*. 26, 8

### **Antibody Glycosylation Predicts Relapse in Autoimmune Vasculitis**

Collin, M., 2017, I: *EBioMedicine*. 17, s. 15 1 s.

### **Bacterial Pathogenesis: Methods and Protocols**

Nordenfelt, P. (redaktör) & Collin, M. (redaktör), 2017, 1 uppl. Humana Press. 357 s. (Methods in Molecular Biology; vol. 1535)

### **BspK, a serine protease from the predatory bacterium *Bdellovibrio bacteriovorus* with utility for analysis of therapeutic antibodies**

Bratanis, E., Molina, H., Nägeli, A., Collin, M. & Lood, R., 2017, I: *Applied and Environmental Microbiology*. 83, 4, e03037-16.

### **From greasy bad guy to superficial savior!**

Collin, M., 2017, I: *Forum for Nordic Dermato-Venerology*. 22, 1, s. 17 1 s.

### **Three variants of the leukotoxin gene in human isolates of *Fusobacterium necrophorum* subspecies *funduliforme***

Holm, K., Collin, M., Hagelskjær-Kristensen, L., Jensen, A. & Rasmussen, M., 2017, I: *Anaerobe*. 45, s. 129-132

### **Toward clinical use of the IgG specific enzymes IdeS and EndoS against antibody-mediated diseases**

Collin, M. & Björck, L., 2017, *Methods in Molecular Biology*. Humana Press, Vol. 1535. s. 339-351 13 s. (Methods in Molecular Biology; vol. 1535).

### **CP40 from *Corynebacterium pseudotuberculosis* is an endo- $\beta$ -N-acetylglucosaminidase**

Shadnezhad, A., Nägeli, A. & Collin, M., 2016 nov. 8, I: *BMC Microbiology*. 16, 1, 10 s.

### **EndoSd: An IgG glycan hydrolyzing enzyme in *Streptococcus dysgalactiae* subspecies *dysgalactiae***

Shadnezhad, A., Nägeli, A., Sjögren, J., Adamczyk, B., Leo, F., Allhorn, M., Karlsson, N. G., Jensen, A. & Collin, M., 2016 juni 1, I: *Future Microbiology*. 11, 6, s. 721-736 16 s.

### **A Monosaccharide Residue Is Sufficient to Maintain Mouse and Human IgG Subclass Activity and Directs IgG Effector Functions to Cellular Fc Receptors.**

Kao, D., Danzer, H., Collin, M., Groß, A., Eichler, J., Stambuk, J., Lauc, G., Lux, A. & Nimmerjahn, F., 2015, I: *Cell Reports*. 13, 11, s. 2376-2385

### **EndoS and EndoS2 hydrolyze Fc-glycans on therapeutic antibodies with different glycoform selectivity and can be used for rapid quantification of high-mannose glycans.**

Sjögren, J., Cosgrave, E., Allhorn, M., Nordgren, M., Björck, S., Olsson, F., Fredriksson, S. & Collin, M., 2015, I: *Glycobiology*. 25, 10, s. 1053-1063

### **Bacterial glycosidases in pathogenesis and glycoengineering.**

Sjögren, J. & Collin, M., 2014, I: *Future Microbiology*. 9, 9, s. 1039-1051

### **EndoE from *Enterococcus faecalis* Hydrolyzes the Glycans of the Biofilm Inhibiting Protein Lactoferrin and Mediates Growth.**

Garbe, J., Sjögren, J., Cosgrave, E. F. J., Struwe, W. B., Bober, M., Olin, A., Rudd, P. M. & Collin, M., 2014, I: PLoS ONE. 9, 3, e91035.

**EndoS Reduces the Pathogenicity of Anti-mCOL7 IgG through Reduced Binding of Immune Complexes to Neutrophils.**  
Yu, X., Zheng, J., Collin, M., Schmidt, E., Zillikens, D. & Petersen, F., 2014, I: PLoS ONE. 9, 2, e85317.

**Fcγ Receptors III and IV Mediate Tissue Destruction in a Novel Adult Mouse Model of Bullous Pemphigoid.**

Schulze, F. S., Beckmann, T., Nimmerjahn, F., Ishiko, A., Collin, M., Köhl, J., Goletz, S., Zillikens, D., Ludwig, R. & Schmidt, E., 2014, I: American Journal of Pathology. 184, 8, s. 2185-2196

**Bacterial Modulation of Fc Effector Functions**

Collin, M. & Kilian, M., 2013 sep. 1, *Antibody Fc: Linking Adaptive and Innate Immunity*. Elsevier, s. 317-332 16 s.

**Dominant suppression of inflammation by glycan-hydrolyzed IgG [Retracted]**

Nandakumar, K. S., Collin, M., Happonen, K., Croxford, A. M., Lundstrom, S. L., Zubarev, R. A., Rowley, M. J., Blom, A. & Holmdahl, R., 2013, I: Proceedings of the National Academy of Sciences. 110, 25, s. 10252-10257

**EndoS2 is a unique and conserved enzyme of serotype M49 group A Streptococcus that hydrolyses N-linked glycans on IgG and α1-acid glycoprotein**

Sjögren, J., Struwe, W. B., Cosgrave, E. F. J., Rudd, P. M., Stervander, M., Allhorn, M., Hollands, A., Nizet, V. & Collin, M., 2013, I: Biochemical Journal. 455, 1, s. 107-118

**Human Chemokines as Antimicrobial Peptides with Direct Parasiticidal Effect on Leishmania mexicana In Vitro.**

Karlsson Söbirk, S., Mörgelin, M., Egesten, A., Bates, P., Shannon, O. & Collin, M., 2013, I: PLoS ONE. 8, 3, e58129.

**The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies.**

Collin, M. & Ehlers, M., 2013, I: Experimental Dermatology. 22, 8, s. 511-514

**The protective effect of immunoglobulin in murine tuberculosis is dependent on IgG glycosylation**

Olivares, N., Marquina, B., Mata-Espinoza, D., Zatarain-Barron, Z. L., Espitia Pinzon, C., Estrada, I., Parada, C., Collin, M., Rook, G. & Hernandez-Pando, R., 2013, I: Pathogens and Disease. 69, 3, s. 176-183

**Bacterial Hydrolysis of Host Glycoproteins - Powerful Protein Modification and Efficient Nutrient Acquisition.**

Garbe, J. & Collin, M., 2012, I: Journal of Innate Immunity. 4, 2, s. 121-131

**Characterization of Released Polypeptides During an Interferon-γ-Dependent Antibacterial Response in Airway Epithelial Cells.**

Eliasson, M., Olin, A., Malmström, J., Mörgelin, M., Bodelsson, M., Collin, M. & Egesten, A., 2012, I: Journal of Interferon and Cytokine Research. 32, 11, s. 524-533

**Enzymatic autoantibody glycan hydrolysis alleviates autoimmunity against type VII collagen**

Hirose, M., Vafia, K., Kalies, K., Groth, S., Westermann, J., Zillikens, D., Ludwig, R. J., Collin, M. & Schmidt, E., 2012, I: Journal of Autoimmunity. 39, 4, s. 304-314

**IgG glycan hydrolysis by endoglycosidase S diminishes the proinflammatory properties of immune complexes from patients with systemic lupus erythematosus: A possible new treatment?**

Lood, C., Allhorn, M., Lood, R., Gullstrand, B., Olin, A., Ronnblom, L., Truedsson, L., Collin, M. & Bengtsson, A., 2012, I: Arthritis and Rheumatism. 64, 8, s. 2698-2706

**IgG glycan hydrolysis by EndoS diminishes the pro-inflammatory properties of immune complexes from patients with SLE - a possible new treatment?**

Lood, C., Allhorn, M., Lood, R., Gullstrand, B., Olin, A., Rönblom, L., Truedsson, L., Collin, M. & Bengtsson, A., 2012, I: Arthritis and Rheumatism. 71, Suppl 1

**IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis**

Benkhoucha, M., Molnarfi, N., Santiago-Raber, M.-L., Weber, M. S., Merkler, D., Collin, M. & Lalive, P. H., 2012, I: Journal of Neuroinflammation. 9, 209

**Tolerance induction with T cell-dependent protein antigens induces regulatory sialylated IgGs**

Oefner, C. M., Winkler, A., Hess, C., Lorenz, A. K., Holecska, V., Huxdorf, M., Schommartz, T., Petzold, D., Bitterling, J., Schoen, A.-L., Stoehr, A. D., Van, D. V., Darcan-Nikolaisen, Y., Blanchard, V., Schmutte, I., Laumonnier, Y., Stroever, H. A., Hegazy, A. N., Eiglmeier, S. & Schoen, C. T. och 13 andra, Mertes, M. M. M., Loddenkemper, C., Loehning, M., Koenig, P., Petersen, A., Luger, E. O., Collin, M., Koehl, J., Hutloff, A., Hamelmann, E., Berger, M., Wardemann, H. & Ehlers, M., 2012, I: Journal of Allergy and Clinical Immunology. 129, 6, s. 1647

**Bacteria can help us cure autoimmune disease**

Collin, M., 2011 dec. 21, The Irish Times, 2011, Dec 21, s. 1 1 s.

**Bacteria can help us cure autoimmune disease**

Collin, M., 2011 dec. 16, El Pais, 2011, Dec 16, s. 1 1 s.

**Belöna universitet som förbättrar jämställdheten**

Sandvik Wiklund, P., Anvret, M., Collin, M., Eriksson, E., Eriksson, P., Glad, C., Höök, P. & Mellström, U., 2011 jan. 21, Dagens nyheter (DN debatt), 2011, Jan 21, s. 6.

**Antibacterial activity of the contact and complement systems is blocked by SIC, a protein secreted by Streptococcus pyogenes.**

Frick, I.-M., Shannon, O., Åkesson, P., Mörgelin, M., Collin, M., Schmidtchen, A. & Björck, L., 2011, I: Journal of Biological Chemistry. 286, s. 1331-1340

**Characterization and genome sequencing of two Propionibacterium acnes phages displaying pseudolysogeny**

Lood, R. & Collin, M., 2011, I: BMC Genomics. 12

**Cysteine proteinase SpeB from Streptococcus pyogenes - a potent modifier of immunologically important host and bacterial proteins**

Nelson, D. C., Garbe, J. & Collin, M., 2011, I: Biological Chemistry. 392, 12, s. 1077-1088

**Study of the IgG endoglycosidase EndoS in group A streptococcal phagocyte resistance and virulence**

Sjögren, J., Okumura, C. Y. M., Collin, M., Nizet, V. & Hollands, A., 2011, I: BMC Microbiology. 11

**The Membrane Bound LRR Lipoprotein Slr, and the Cell Wall-Anchored M1 Protein from Streptococcus pyogenes Both Interact with Type I Collagen**

Bober, M., Mörgelin, M., Olin, A., von Pawel-Rammingen, U. & Collin, M., 2011, I: PLoS ONE. 6, 5

**Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus**

Daniel, A., Euler, C., Collin, M., Chahales, P., Gorelick, K. J. & Fischetti, V. A., 2010 apr. 1, I: Antimicrobial Agents and Chemotherapy. 54, 4, s. 1603-1612 10 s.

**Collagen VI Is a Subepithelial Adhesive Target for Human Respiratory Tract Pathogens**

Bober, M., Enochsson, C., Collin, M. & Mörgelin, M., 2010, I: Journal of Innate Immunity. 2, 2, s. 160-166

**IgG Glycan Hydrolysis Attenuates ANCA-Mediated Glomerulonephritis**

van Timmeren, M. M., van der Veen, B. S., Stegeman, C. A., Petersen, A. H., Hellmark, T., Collin, M. & Heeringa, P., 2010, I: Journal of the American Society of Nephrology. 21, 7, s. 1103-1114

**Midkine and pleiotrophin have bactericidal properties - preserved antibacterial activity in a family of heparin-binding growth factors during evolution.**

Nordin, S., Pasupuleti, M., Walse, B., Malmsten, M., Mörgelin, M., Sjogren, C., Olin, A., Collin, M., Schmidtchen, A., Palmer, R. & Egesten, A., 2010, I: *Journal of Biological Chemistry*. 285, 21, s. 16105-16115

**Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes**

Yang, R., Otten, M. A., Hellmark, T., Collin, M., Björck, L., Zhao, M.-H., Daha, M. R. & Segelmark, M., 2010, I: *Nephrology Dialysis Transplantation*. 25, 8, s. 2479-2486

**The IgG specific endoglycosidase EndoS inhibits both cellular and complement mediated autoimmune hemolysis.**

Allhorn, M., Briceño, J. G., Baudino, L., Lood, C., Olsson, M. L., Izui, S. & Collin, M., 2010, I: *Blood*. 115, 24, s. 5080-5088

**Contributions to Microbiology: Foreword**

Collin, M. & Schuch, R., 2009 jan. 1, *Bacterial Sensing and Signaling*. Karger, 2 s. (Contributions to Microbiology; vol. 16).

**Bacterial Sensing and Signaling**

Collin, M. (redaktör) & Schuch, R. (redaktör), 2009, Karger. 238 s. (Contributions to Microbiology; vol. 16)

**Biofilm formation by *Propionibacterium acnes* is a characteristic of invasive isolates.**

Holmberg, A., Lood, R., Mörgelin, M., Söderquist, B., Holst, E., Collin, M., Christensson, B. & Rasmussen, M., 2009, I: *Clinical Microbiology and Infection*. 15, s. 787-795

**SpeB of *Streptococcus pyogenes* differentially modulates antibacterial and receptor activating properties of human chemokines.**

Egesten, A., Olin, A., Linge, H., Yadav, M., Mörgelin, M., Karlsson, A. & Collin, M., 2009, I: *PLoS ONE*. 4, 3, e4769.

**SufA - a bacterial enzyme that cleaves fibrinogen and blocks fibrin network formation.**

Karlsson, C., Mörgelin, M., Collin, M., Lood, R., Andersson, M.-L., Schmidtchen, A., Björck, L. & Frick, I.-M., 2009, I: *Microbiology*. 155, Pt 1, s. 238-248

**Sugar-free antibodies—the bacterial solution to autoimmunity?**

Allhorn, M. & Collin, M., 2009, I: *Annals of the New York Academy of Sciences*. 1173, s. 664-669

**The human CXC chemokine granulocyte chemotactic protein 2 (GCP-2)/CXCL6 possesses membrane-disrupting properties and is antibacterial**

Linge, H. M., Collin, M., Nordenfelt, P., Mörgelin, M., Malmsten, M. & Egesten, A., 2008 juli, I: *Antimicrobial Agents and Chemotherapy*. 52, 7, s. 2599-2607 9 s.

**Constitutive expression of the antibacterial CXC chemokine GCP-2/CXCL6 by epithelial cells of the male reproductive tract.**

Collin, M., Linge, H., Bjartell, A., Giwercman, A., Malm, J. & Egesten, A., 2008, I: *Journal of Reproductive Immunology*. 79, s. 37-43

**EndoS from *Streptococcus pyogenes* is hydrolyzed by the cysteine proteinase SpeB and requires glutamic acid 235 and tryptophans for IgG glycan-hydrolyzing activity**

Allhorn, M., Olsén, A. & Collin, M., 2008, I: *BMC Microbiology*. 8, 1, 3.

**Enzymatically Generated Low Carbohydrate Antibodies as a Novel Treatment for Autoimmune Disease**

Allhorn, M., Nimmerjahn, F., Izui, S. & Collin, M., 2008, I: *Glycobiology*. 18, 11, s. 58

**Human IgG/Fcγ<sub>3</sub>R Interactions Are Modulated by Streptococcal IgG Glycan Hydrolysis.**

Allhorn, M., Olin, A. I., Nimmerjahn, F. & Collin, M., 2008, I: *PLoS ONE*. 3, 1, e1413.

**IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions.**

Collin, M., Shannon, O. & Björck, L., 2008, I: Proceedings of the National Academy of Sciences. 105, 11, s. 4265-4270

**Inducible Siphoviruses in superficial and deep tissue isolates of Propionibacterium acnes**

Lood, R., Mörgelin, M., Holmberg, A., Rasmussen, M. & Collin, M., 2008, I: BMC Microbiology. 8

**In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner**

Albert, H., Collin, M., Dudziak, D., Ravetch, J. V. & Nimmerjahn, F., 2008, I: Proceedings of the National Academy of Sciences. 105, 39, s. 15005-15009

**Rapid DNA library construction for functional genomic and metagenomic screening**

Schmitz, J. E., Daniel, A., Collin, M., Schuch, R. & Fischetti, V. A., 2008, I: Applied and Environmental Microbiology. 74, 5, s. 1649-1652

**The Antibacterial Chemokine MIG/CXCL9 Is Constitutively Expressed in Epithelial Cells of the Male Urogenital Tract and Is Present in Seminal Plasma.**

Linge, H., Collin, M., Giwercman, A., Malm, J., Bjartell, A. & Egesten, A., 2008, I: Journal of Interferon and Cytokine Research. 28, 3, s. 190-196

**Kan man snacka bort representativ demokrati?**

Collin, M., 2007 maj, Medicinska fakultetens personaltidning - närv, 2007, May, s. 12-12 1 s.

**Endoglycosidase treatment abrogates IgG arthritogenicity: Importance of IgG glycosylation in arthritis.**

Kutty Selva, N., Collin, M., Olsén, A., Nimmerjahn, F., Blom, A., Ravetch, J. V. & Holmdahl, R., 2007, I: European Journal of Immunology. 37, 10, s. 2973-2982

**M1 protein of Streptococcus pyogenes increases production of the antibacterial CXC chemokine MIG/CXCL9 in pharyngeal epithelial cells**

Eliasson, M., Frick, I.-M., Collin, M., Sørensen, O. E., Björck, L. & Egesten, A., 2007, I: Microbial Pathogenesis. 43, 5-6, s. 224-233

**Monitor – biology**

Collin, M., Spitzer, E. D., Williams, R., Dass, C. R. & Egan, T. J., 2005, I: Drug Discovery Today. 10, 17, s. 1201-1203

**Monitor – biology**

Collin, M., James, W., Andrawiss, M., Heath, V., Noble, C. & Cheung, H. H., 2005, I: Drug Discovery Today. 10, 1, s. 75-77

**Monitor – biology**

Collin, M. & Cheung, H. H., 2005, I: Drug Discovery Today. 10, 15, s. 1073

**Monitor – biology**

Collin, M., Spitzer, E. D. & Andrawiss, M., 2005, I: Drug Discovery Today. 10, 7, s. 530-531

**A Novel secreted endoglycosidase from Enterococcus faecalis with activity on human immunoglobulin G and ribonuclease B**

Collin, M. & Fischetti, V. A., 2004 maj 21, I: Journal of Biological Chemistry. 279, 21, s. 22558-22570 13 s.

**Biology**

Collin, M., Wilson, J., Kruidering, M., Laine, M. & Noble, C., 2004, I: Drug Discovery Today. 9, 9, s. 420-422

**Biology**

Collin, M., Ringrose, L., Gunzer, M., Haefner, B. & Lyddy, F., 2004, I: Drug Discovery Today. 9, 7, s. 338-340

## **Biology**

Zielinski, D., Henkel, T., Wojcik, C., Egan, T. J., Wilson, J. W., Collin, M., Lawrence, N. S. & Schetters, T. P., 2004, I: Drug Discovery Today. 9, 3, s. 147-150

## **Don't forget about Streptococcus pyogenes! (comment on Microbes Infect. 5 (2003) 1329-1335)**

Collin, M., 2004, I: Microbes and Infection. 6, 3, s. 336-336

## **Low Antibody Levels against Cell Wall-Attached Proteins of Streptococcus pyogenes Predispose for Severe Invasive Disease.**

Åkesson, P., Rasmussen, M., Mascini, E., von Pawel-Rammingen, U., Janulczyk, R., Collin, M., Olsen, A., Mattsson, E., Olsson, M. L., Björck, L. & Christensson, B., 2004, I: Journal of Infectious Diseases. 189, 5, s. 797-804

## **Monitor – biology**

Collin, M., Andrawiss, M., Demidov, V. V., Haefner, B. & Heath, V., 2004, I: Drug Discovery Today. 9, 19, s. 856-858

## **Monitor – biology**

Spitzer, E., Collin, M., Noble, C., Zielinski, D., Henkel, T., Olivares-Reyes, J. A., Morquecho-León, M. A., Barnes, M. & Miller, D. J., 2004, I: Drug Discovery Today. 9, 21, s. 941-943

## **Monitor – biology**

Sahin, A., Bakalara, N., Collin, M., Olivares-Reyes, J. A., Arellano-Plancarte, A., Zielinski, D., Henkel, T. & Heath, V., 2004, I: Drug Discovery Today. 9, 16, s. 722-724

## **Monitor – biology**

Heath, V., Noble, C., Demidov, V. V., Barnes, M., Miller, D. J., Collin, M., Lain, M. & Egan, T. J., 2004, I: Drug Discovery Today. 9, 15, s. 678-681

## **Monitor – Biology**

Cheung, H. H., Noble, C., Hooft, R. & Collin, M., 2004, I: Drug Discovery Today. 9, 14, s. 621-622

## **Monitor – Biology**

Collin, M., Noble, C., Heath, V., Zielinski, D., Henkel, T. & Davies, W., 2004, I: Drug Discovery Today. 9, 12, s. 539-541

## **Monitor – Biology**

Cheung, H. H., Kruidering, M., Noble, C. G., Miller, D. J., Barnes, M. J., Gao, G. F., Collin, M., Chen, S. & Hooft van Huijsdijnen, R., 2004, I: Drug Discovery Today. 9, 6, s. 287-290

## **Monitor – Biology**

Collin, M., Ilag, L. L., Hooft, R. & Andrawiss, M., 2004, I: Drug Discovery Today. 9, 24, s. 1082-1084

## **Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes**

Collin, M. & Olsén, A., 2003, I: Infection and Immunity. 71, 6, s. 2983-2992

## **EndoS and SpeB from Streptococcus pyogenes inhibit immunoglobulin-mediated opsonophagocytosis.**

Collin, M., Svensson, M., Sjöholm, A., Jensenius, J. C., Sjöbring, U. & Olsén, A., 2002, I: Infection and Immunity. 70, 12, s. 6646-6651

## **Effect of SpeB and EndoS from Streptococcus pyogenes on human immunoglobulins**

Collin, M. & Olsén, A., 2001, I: Infection and Immunity. 69, 11, s. 7187-7189

## **EndoS, a novel secreted protein from Streptococcus pyogenes with endoglycosidase activity on human IgG**

Collin, M. & Olsén, A., 2001, I: EMBO Journal. 20, 12, s. 3046-3055

**Identification of conditionally expressed genes in Streptococcus pyogenes using RNA fingerprinting**  
Collin, M. & Olsén, A., 2001, I: FEMS Microbiology Letters. 196, 2, s. 123-127

**Streptococcus pyogenes secreted enzymes interacting with the human host**  
Collin, M., 2001, BMC Biomedical Centre, Lund University. 138 s.

**Generation of a mature streptococcal cysteine proteinase is dependent on cell wall-anchored M1 protein**  
Collin, M. & Olsén, A., 2000, I: Molecular Microbiology. 36, 6, s. 1306-1318

**Protein H, an antiphagocytic surface protein in Streptococcus pyogenes**  
Kihlberg, B. M., Collin, M., Olsén, A. & Björck, L., 1999, I: Infection and Immunity. 67, 4, s. 1708-1714

**Streptococcal cysteine proteinase releases kinins: a novel virulence mechanism**  
Herwald, H., Collin, M., Muller-Esterl, W. & Björck, L., 1996, I: Journal of Experimental Medicine. 184, 2, s. 665-673

## Aktiviteter

**Bacterial antibody hydrolyzing enzymes - as bacterial virulence factors and novel biotechnological tools - Eleni Bratanis**  
Collin, M. (Första/primär/huvudhandledare)  
2019 okt. 25

**Leishmaniasis in Sweden - Molecular, diagnostic and epidemiological studies of the parasite Leishmania in a non-endemic country - Sara Karlsson Söbirk**  
Collin, M. (Första/primär/huvudhandledare)  
2019 apr. 5

**Bacterial IgG modulating enzymes - Basic biology and biotechnological applications - Azadeh Shadnezhad**  
Collin, M. (Första/primär/huvudhandledare)  
2017 feb. 3

**Bacterial modulation of host glycosylation – in infection, biotechnology, and therapy - Jonathan Sjögren**  
Collin, M. (Första/primär/huvudhandledare)  
2015 mars 13

**Molecular and microscopical analysis of pathogenic streptococci - studies on surface proteins interacting with human cells and extracellular matrix - Marta Bober**  
Collin, M. (Första/primär/huvudhandledare)  
2011 nov. 4

**Propionibacterium acnes and its phages - Rolf Lood**  
Collin, M. (Första/primär/huvudhandledare)  
2011 okt. 7

## Priser och utmärkelser

**Åke Wiberg million grant recipient (2012-2014)**  
Collin, M. (Mottagare), 2012

**Prize for best project application and Anniversary medal in silver**  
Collin, M. (Mottagare), 2009

**The Florman award (Flormanska belöningen)**

Collin, M. (Mottagare), 2010

**Translational Research Award**

Collin, M. (Mottagare), 2012

**Projekt**

**Enzymatic antibody glycan modifications as treatment against acute and chronic autoimmune diseases**

Collin, M. (PI)

2017/01/01 → 2017/12/31

**Enzymatisk antikroppsmodifiering vid bakteremi – diagnostiska, profylaktiska och terapeutiska implikationer**

Collin, M. (PI), Holm, K. (CoPI), Sunnerhagen, T. (Forskare) & Rasmussen, M. (Forskare)

2023/01/01 → 2026/12/31

**Neutralizing human B-cell derived monoclonal antibodies to SARS-CoV-2**

Nordenfelt, P. (PI), Bahnan, W. (Forskare), Rasmussen, M. (Forskare), Kahn, F. (Forskare), Björck, L. (Forskare), Shannon, O. (Forskare), Collin, M. (Forskare), Malmström, J. (Forskare) & Kahn, R. (Forskare)

Science for Life Laboratory

2020/04/08 → 2021/01/31

**Streptokockers modifiering av antikroppars glykosylering vid allvarliga infektioner**

Collin, M. (PI)

2018/01/01 → 2020/12/31